
|Articles|June 10, 2004
FDA approves new oral drug for overactive bladder
Trospium chloride (Sanctura) has been approved by the FDA for the treatment of overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants fast track designation to diagnostic agent for clear cell renal cell carcinoma
2
Expert: Biomarker-driven care set to shape future of prostate cancer management
3
Why team-based care is now essential for muscle-invasive bladder cancer
4



















